The ANKRD28 Knockout A-549 Polyclonal Cells product consists of a CRISPR/Cas9-edited polyclonal knockout cell population of A-549 human lung carcinoma cells with targeted disruption of the ANKRD28 gene, generating a loss-of-function model. This polyclonal format maintains genetic diversity and is well-suited for pooled screening and initial mechanistic investigations without clonal selection. Researchers can utilize these cells to examine ANKRD28-dependent signaling in a lung adenocarcinoma background.
The A-549 cell line was originally established from a human lung adenocarcinoma and serves as a model of alveolar type II epithelial cells. It carries an activating KRAS mutation and expresses wild-type p53, reflecting key oncogenic features of non-small cell lung cancer. A-549 cells exhibit adherent epithelial morphology and respond to growth factor stimulation, making them a valuable platform for cancer cell biology and signal transduction studies.
ANKRD28 acts as a targeting subunit for protein phosphatase 1 (PP1), directing catalytic subunits (PPP1CA, PPP1CB, PPP1CC) to specific subcellular sites via ankyrin repeat-mediated protein interactions. It primarily tethers PP1 to the actin cytoskeleton, where it dephosphorylates substrates including cofilin (CFL1) and possibly RB1. Disruption of ANKRD28 impairs PP1-dependent dephosphorylation of these effectors, likely altering cytoskeletal organization, cell adhesion, and cell cycle progression. Key downstream readouts include phosphorylated CFL1 and PP1 holoenzyme assembly, assessable by western blotting and co-immunoprecipitation.
Within the KRAS-mutant, p53 wild-type A-549 lung adenocarcinoma context, ANKRD28 knockout may reveal PP1 targeting functions critical for cancer cell migration, proliferation, and focal adhesion dynamics. Loss of ANKRD28 could dysregulate cytoskeletal remodeling controlled by cofilin phosphorylation and perturb RB1-mediated cell cycle control, processes often disrupted in lung cancer. This model enables interrogation of PP1 regulatory networks in oncogenic signaling and may inform therapeutic strategies targeting phosphatase complexes.
Applications include mechanistic studies of PP1 substrate targeting, cytoskeletal regulation in cancer, and validation of ANKRD28 as a drug target in lung adenocarcinoma. Recommended assays comprise western blotting for ANKRD28 and p-CFL1, immunofluorescence of F-actin and focal adhesions, cell migration and proliferation assays, co-immunoprecipitation of PP1 subunits, and phospho-proteomic profiling to capture global changes in protein phosphorylation. These approaches facilitate detailed functional characterization. For more information, please contact Ascent Research.
